Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

Overview of attention for article published in Drug Design, Development and Therapy, October 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

blogs: 1 blog

twitter: 2 X users

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 81 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 9,021 followers.

@NephroGuy @scoca1 @NEJM @ChristosArgyrop Ertugliflozin is an SGLT2i https://t.co/WKdoa0TAQX The dual SGLT1/SGLT2 inhibitor is Sotagliflozin

Reply Repost Favourite

Spotlight on ertugliflozin and its potential in the treatment of diabetes | DDDT @DovePress https://t.co/4MPLRUpIJ6

Reply Repost Favourite